Product Name :
ITSA-1
Description:
ITSA-1 is an activator of histone deacetylase (HDAC), and counteract trichostatin A (TSA)-induced cell cycle arrest, histone acetylation, and transcriptional activation.
CAS:
200626-61-5
Molecular Weight:
292.12
Formula:
C13H7Cl2N3O
Chemical Name:
1-(2,4-dichlorobenzoyl)-1H-1,2,3-benzotriazole
Smiles :
O=C(C1=CC=C(Cl)C=C1Cl)N1N=NC2=CC=CC=C12
InChiKey:
UVNLAUGZMOPBPR-UHFFFAOYSA-N
InChi :
InChI=1S/C13H7Cl2N3O/c14-8-5-6-9(10(15)7-8)13(19)18-12-4-2-1-3-11(12)16-17-18/h1-7H
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
ITSA-1 is an activator of histone deacetylase (HDAC), and counteract trichostatin A (TSA)-induced cell cycle arrest, histone acetylation, and transcriptional activation.|Product information|CAS Number: 200626-61-5|Molecular Weight: 292.12|Formula: C13H7Cl2N3O|Chemical Name: 1-(2,4-dichlorobenzoyl)-1H-1,2,3-benzotriazole|Smiles: O=C(C1=CC=C(Cl)C=C1Cl)N1N=NC2=CC=CC=C12|InChiKey: UVNLAUGZMOPBPR-UHFFFAOYSA-N|InChi: InChI=1S/C13H7Cl2N3O/c14-8-5-6-9(10(15)7-8)13(19)18-12-4-2-1-3-11(12)16-17-18/h1-7H|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : ≥ 32 mg/mL (109.54 mM).|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.{{Panitumumab (anti-EGFR)} web|{Panitumumab (anti-EGFR)} JAK/STAT Signaling|{Panitumumab (anti-EGFR)} Purity & Documentation|{Panitumumab (anti-EGFR)} References|{Panitumumab (anti-EGFR)} supplier|{Panitumumab (anti-EGFR)} Epigenetic Reader Domain} |Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|ITSA1 (50 μM; A549 cells) treatment serves to revert the TSA-arrested population to a normal cell cycle distribution. ITSA1 is also able to effect cell cycle rescue over longer duration.{{Letermovir} site|{Letermovir} Anti-infection|{Letermovir} Protocol|{Letermovir} References|{Letermovir} custom synthesis|{Letermovir} Cancer} ITSA1 (50 μM; 5 hours; A549 cells) treatment reduces the number of apoptosis in TSA-treated cells.PMID:24238415 ITSA1 (50 μM; 2 hours; A549 and murine ES cells cells) treatment suppresses TSA-induced histone acetylation. Importantly, suppression of acetylation levels is only observable when ITSA1 is added concurrent with or post TSA treatment. ITSA1 (50 μM; 30 minutes; murine ES cells cells) suppresses TSA-activated transcription in murine ES cells.|In Vivo:|ITSA-1 (0.5 mg/kg; intraperitoneal injection; 3 times/week; for 8 weeks; CBS+/− mice) treatment balances deacetylation activity and suppresses IL-6 and TNF-α expression and thereby attenuated histone acetylationdependent infammatory signaling.|Products are for research use only. Not for human use.|